Loading clinical trials...
Loading clinical trials...
A Randomized Open Label Phase II Trial of FDG-PET-Guided Metastasis Directed Therapy in Patients With Metastatic Hormone Sensitive Prostate Cancer: PRTY Trial: PET- Guided Radiotherapy Consolidation
Conditions
Interventions
Antiandrogen Therapy
Bone Scan
+4 more
Locations
6
United States
Northwestern University
Chicago, Illinois, United States
Northwestern Medicine: Kishwaukee
DeKalb, Illinois, United States
Northwestern Medicine: Delnor
Geneva, Illinois, United States
Northwestern University Oak Brook IL453
Oak Brook, Illinois, United States
Northwestern Medicine Orland Park
Orland Park, Illinois, United States
Northwestern Medicine: Warrenville
Warrenville, Illinois, United States
Start Date
February 18, 2024
Primary Completion Date
February 18, 2027
Completion Date
February 18, 2028
Last Updated
March 30, 2026
NCT07219147
NCT04693377
NCT06389786
NCT05398302
NCT06526299
NCT04550494
Lead Sponsor
Northwestern University
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions